## Supplementary Information

## Impaired eIF5A function causes a Mendelian disorder that is partially

## rescued in model systems by spermidine

Víctor Faundes, Martin D. Jennings, Siobhan Crilly, Sarah Legraie, Sarah E. Withers, Sara Cuvertino, Sally J. Davies, Andrew G.L. Douglas, Andrew E. Fry, Victoria Harrison, Jeanne Amiel, Daphné Lehalle, William G. Newman, Patricia Newkirk, Judith Ranells, Miranda Splitt, Laura Cross, Carol J. Saunders, Bonnie R Sullivan,
Jorge L. Granadillo, Christopher T. Gordon, Paul R. Kasher, Graham D. Pavitt, Siddharth Banka

## Supplementary Note 1

## Case reports from individuals described in Table 1

## Individual 1; de novo, c. $143 \mathrm{C}>\mathrm{A}$, p.T48N

This is a 6.9 -year-old female born to non-consanguineous, healthy parents. She had congenital microcephaly (head circumference of 31 cm at 1 month old) and intra-uterine growth retardation (birth weight 2260 g ). She has moderate to severe global developmental delay. She walked independently from 24 months of age, and speaks in short sentences with difficult articulation at 6.9 years of age. She has abnormal mineralisation of the skull, bilateral ethmoidal, zygomatic, malar and mandibular hypoplasia, defects of the orbital floor, and hemivertebrae (L3). She does not have cardiac anomalies. She has eyelid hypoplasia, corneal ulceration and strabismus. At 6.8 years of age her height was $119 \mathrm{~cm}(0.5 \mathrm{SD})$, weight was $25.8 \mathrm{Kg}(2 \mathrm{SD})$ and head circumference was $46 \mathrm{~cm}(-3 \mathrm{SD})$. She has sloping forehead, broad eyebrows, small lower eyelids, hypoplastic supraorbital ridges, bulbous nasal tip, microretrognathia, high arched palate, abnormal pinnae, low set ears and short neck. Hands and feet are also short with hypoplastic thumbs with limited metacarpophalangeal flexion, clinodactyly of 5th fingers and brachydactyly of toes. The initial clinical suspicion was a syndromic mandibulofacial dysostosis with microcephaly.

## Individual 2; de novo, c.316G>A, p.G106R

This is an 8.4-year-old female born to consanguineous, healthy parents, without other affected individuals in her family. She had intra-uterine growth retardation, congenital microcephaly and neonatal feeding difficulties. She had a normal computed tomography scan at birth. She was also noted to have cardiac anomalies prenatally. She had a dysplastic tricuspid valve, tricuspid regurgitations and secundum atrial septal defect that were treated surgically at 11 months of age. She has moderate global developmental delay. She could sit unsupported at 18 months, walked independently from 23 months of age, and said her first words from 2.5 years of age. She is fed via a gastrostomy tube. She has constipation and gastroesophageal reflux. At 6.7 years of age her height was $105.3 \mathrm{~cm}(-2.82 \mathrm{SD})$, weight was $16.4 \mathrm{Kg}(-2.28 \mathrm{SD})$ and head circumference was $43.5 \mathrm{~cm}(-7.47 \mathrm{SD})$. She has broad eyebrows, hypoplastic supraorbital ridges, epi- and telecanthus, bulbous nasal tip, thin upper lip, micrognathia and low set ears. The initial clinical suspicion was a Kabuki-like syndrome.

## Individual 3; de novo, c.324dupA, p.R109TfsTer8

This is an 8.4-year-old female born to non-consanguineous, healthy parents. She had congenital microcephaly, a cleft palate, and neonatal feeding difficulties. The cleft palate was corrected surgically. She was also noted to have cardiac anomalies neonatally. She had a functional bicuspid aortic valve with fusion of the left and right coronary cusps, and trace aortic regurgitation. However, by 3 years of age her heart scan showed a structurally and functionally normal heart with a trileaflet aortic valve. She had mild global developmental delay and autistic traits. She walked independently from 17 months of age and said her first word from 12 months of age. She has conductive deafness that required grommets, premature thelarche and joint hypermobility. No ophthalmological, urogenital, immunity or brain anomalies have been detected. At 26 months of age her height was 90.3 cm ( 0.86 SD), weight was $11.3 \mathrm{Kg}(-0.41 \mathrm{SD})$ and head circumference was $44.5 \mathrm{~cm}(-2.11 \mathrm{SD})$. She has broad eyebrows, hypoplastic supraorbital ridges, epi- and telecanthus, hypertelorism, bulbous nasal tip, thin upper lip and micrognathia. The initial clinical suspicion was a Kabuki-like syndrome.

## Individual 4; de novo, c. $325 \mathrm{C}>\mathrm{G}$, p.R109G

This is an 18.3 -year-old male born to non-consanguineous, healthy parents. He had intra-uterine growth retardation, neonatal hypotonia, and neonatal feeding difficulties. He had mild global developmental delay. He could sit unsupported at 1 year of age, walked independently from 1.5 years of age, and said his first words from 12 months of age. He has an IQ level of 50 . He has small bilateral high intensity signals in the peritrigonal regions of the deep frontoparietal white matter. He is not known to have cardiac anomalies, but has not had any cardiac imaging. He has constipation, glaucoma, cryptorchidism and joint hypermobility. At 17.4 years of age his height was $172.5 \mathrm{~cm}(-0.45 \mathrm{SD})$, weight was $66.4 \mathrm{Kg}(0.06 \mathrm{SD})$ and head circumference was $52.2 \mathrm{~cm}(-2.62$ SD). He has broad eyebrows, prominent supraorbital ridges, epicanthus, long eyelashes, malar hypoplasia, prominent ears, bulbous nasal tip, thin upper lip, micrognathia, pes planus, and sandal gap. The initial clinical suspicion was a Kabuki-like syndrome.

## Individual 5; de novo, c.325C>T, p.R109*

This is an eight-month-old male born to non-consanguineous, healthy parents. The pregnancy was complicated by maternal hypertension and early pre-eclampsia and polyhydramnios. He was delivered at 35 weeks 4 days gestation and weighed 3.20 Kg . He initially required positive pressure ventilation for poor respiratory. He
required feeding via a naso gastric tube feeding and a gastrostomy tube was placed at four months of age due to continued poor growth and oral aversion. He has developmental delays with minimal babbling and poor head control at eight months of age. He could roll from belly to back but could not sit unassisted. He has an atrial septal defect, moderate right atrial enlargement and mild right ventricular dilation. He has been diagnosed with dysphagia and failure to thrive. At eight months of age, his length was $68 \mathrm{~cm}(-1.45 \mathrm{SD})$, weight was 6.18 Kg (3.14 SD) and head circumference was $43 \mathrm{~cm}(-0.45 \mathrm{SD})$. Dysmorphic features noted on physical exam included plagiocephaly, sparse/furry scalp hair, frontal bossing, epicanthal folds, sparse eyebrows, downslanting palpebral fissures, cupped and prominent ears, an ear lobe crease on the right ear, a thin upper lip, and paucity of subcutaneous fat. Physical exam also noted hypotonia with a significant head lag and the inability to sit independently. His initial clinical suspicion was Mowat-Wilson-like syndrome

## Individual 6; de novo, c. $343 \mathrm{C}>\mathrm{T}$; p.P115S

This is a 4-years 8 month-old male born to non-consanguineous, healthy parents. He had no prenatal and neonatal anomalies. He has global developmental delay. He walked independently from 18 months of age, and said his first words at 2 years of age. He spoke in full sentences at almost 4 years. He has no major malformations. He has mild diffuse hypotonia, esophoria, anxiety-induced tic. At 4 years 8 months of age his height was $111.7 \mathrm{~cm}(+1 \mathrm{SD})$, weight was $17.6 \mathrm{Kg}(-0.09 \mathrm{SD})$ and head circumference was $49 \mathrm{~cm}(-1.09 \mathrm{SD})$. On physical exam, he was found to be thin. He had long palpebral fissures (length at the $90^{\text {th }}$ percentile), broad eyebrows and protruding ears bilaterally. He also had micrognathia, a high-arched palate, a long nasal bridge with small ala nasi. Flat feet were noticed bilaterally, with talus pronation.

## Individual 7; de novo, c.364G>A, p.E122K

This is a 16.4-year-old female born to non-consanguineous, healthy parents. She had foetal ascites, which spontaneously resolved prenatally, and positional talipes. She had moderate global developmental delay. She could sit unsupported at 9 months, walked independently from 3 years of age, and said her first words from 3 years of age. She has also autism spectrum disorder and attention deficit hyperactivity disorder. She does not have brain anomalies. She is not known to have cardiac anomalies, but has not had any cardiac imaging. She has left convergent strabismus, nasal polyps, and delayed puberty. At 16 years of age her height was 147.6 cm (2.59 SD), weight was $61.95 \mathrm{Kg}(-0.69 \mathrm{SD})$ and head circumference was $52.7 \mathrm{~cm}(-1.94 \mathrm{SD})$. She has epicanthus, deep-set eyes, prominent creasing and lacrimal punctae of the lower eyelids, small low-set ears, unilateral single palmar crease, small $4^{\text {th }}$ and $5^{\text {th }}$ toenails, contractures of the $5^{\text {th }}$ toes and pes planus. The initial clinical suspicion was of an unidentified genetic syndrome.

## Supplementary Note 2

## heIF5A-WT gene sequence

ggcTCGAGtctgaggggtgagaacagcaaaacgggaacggcgacttggagtagtataacgctgtagctggacgct gaggggccaaggccggtaaaattctgcaacacccagaccttgctgcagtgatatcatccacccatacccctcgat gtattccgtagcgttatatcgggtccgtgtgaggcgacaagggacctcccgcaccgcacataccgcaggagctaa aagaaacgccgtcgcccgaaaaaaagtttcgaaggtgaaggaacagtggtaataaaaatttttttcgtcgtcgtc gtcgatcggcttttggccgcgttgatcgtcgtgttccacgattatataatgcacaaggtttttgccatatcttga cattggaatccctcatttcctaaattcctctccttctatcaattgcttcctttccttctttctaacgattctact tctgtagccaattactcatagactcccaaacacacacaaataccaactcatatatacaATGGCTGACGACTTGGA CTTTGAAACTGGTGACGCTGGTGCCTCCGCCACCTTCCCAATGCAATGTTCTGCCTTGAGAAAGAACGGTTTCGT TGTCTTGAAGGGTAGACCATGTAAGATTGTCGAAATGTCCACTTCTAAGACTGGTAAGCACGGTCACGCTAAAGT CCATTTGGTTGGTATTGATATCTTCACTGGTAAGAAGTATGAAGATATTTGTCCATCTACTCACAACATGGATGT TCCAAATATTAAGAGAAACGATTTCCAATTGATTGGTATTCAAGACGGTTACTTGTCTTTGTTGCAAGATTCTGG TGAAGTTAGAGAGGACCTTCGTCTCCCTGAAGGTGATTTGGGTAAGGAAATTGAACAGAAGTATGATTGTGGTGA AGAAATTTTGATTACCGTCTTGTCCGCTATGACTGAAGAAGCCGCCGTCGCCATCAAGGCAATGGCTAAGTAAac cggttaacatcatggcatgggatataaatgaaaaaagaaaaaaaaactccgacgccccttccatcacatcatgta ctcttcgctgaaccgggtttttttctttgcaatttttttttcgttctcctaaagcatacacaaataaatcctttt ttttattttctatttattttgttatttatcatctatatagcaataatatactttgtttttattcgtatttcacac ttttctttttccttatgcaggcagtgtaattcattggggaggatgattttcatgtgcgcatatctaccggctgca agcagccggtcggtggcaaatccggcgcttccccctcaaaaaaaaaaaaaaaaaaaaaaagggaactctcaAC TAGTgg

## Color key:

Additional GG, Xho1 restriction site, yeast $5^{\prime}-500$ bases, human EIF5A ORF optimised for yeast codon usage, yeast 3'-375 bases, Spe 1 restriction site.

Supplementary Table 1. List of plasmids used in this study.

| Plasmid | Precursor | Description | Source |
| :--- | :--- | :--- | :--- |
| pAV1360 | YCplac111 | sc LEU2 | ${\text { Rizzardi, et al. }{ }^{1}}^{\text {pAV2565 }}$ |
| pC3294 | sc pEU2 yeIF5A-S149P | ${\text { Saini, et al. }{ }^{2}}^{\text {p }}$. |  |

Abbreviations used: $h$ :human (human protein sequence with yeast optimised codon usage), hc: high copy number ( 2 micron) plasmid, sc: single copy number (centromeric) plasmid, $y$ : yeast.

Supplementary Table 2. Sequences of primers used for site-directed mutagenesis.

| Variant ${ }^{\text {a }}$ (CDS; Protein) | Direction | Primer (5'-3') |
| :---: | :---: | :---: |
| c.143C>A; p.T48N | Forward | CCACTTCTAAGAATGGTAAGCACGGTCACGCTAAAGTCC |
|  | Reverse | CCGTGCTTACCATTCTTAGAAGTGGACATTTCGACAATC TTAC |
| c.316G>A; p.G106R | Forward | GCAAGATTCTCGTGAAGTTAGAGAGGACCTTCGTC |
|  | Reverse | CTCTAACTTCACGAGAATCTTGCAACAAAGACAAGTAA CCG |
| c. $324 \mathrm{dupA}{ }^{\text {b }}$; | Forward | GGTGAAGTTACGAGAGGACCTTCGTCTCCCTG |
| p.R109Tfs*8 | Reverse | AGGTCCTCTCGTAACTTCACCAGAATCTTGCAACAAAG |
| c. $364 \mathrm{G}>\mathrm{A} ;$ p.E122K | Forward | GTGATTTGGGTAAGAAAATTGAACAGAAGTATGATTGT GGTGAAG |
|  | Reverse | CTGTTCAATTTTCTTACCCAAATCACCTTCAGGGAGACG |
| ${ }^{\text {a }}$ As detected in individuals |  |  |
| ${ }^{\mathrm{b}}$ For optimising the translation according to yeast codon usage but keeping the predicted truncated amino acid sequence of EIF5A seen in individual 3, the dupA was replaced by insC <br> Abbreviation: CDS=Coding sequence |  |  |

Supplementary Table 3. List of yeast strains created and used in this study.

| Strain | Precursor | Genotype ${ }^{\text {a }}$ |
| :---: | :---: | :---: |
| J696 |  | pAV2571(pC3288)[yeIF5AURA3] |
| GP7439 | J696 | pAV2571[yeIF5A URA3] pAV2569 [yeIF5A LEU2] |
| GP7440 | GP7439 | pAV2569[yeIF5A LEU2] |
| GP7441 | J696 | pAV2571[yeIF5A URA3] pAV2580[heIF5ALEU2] |
| GP7443 | J696 | pAV2571[yeIF5A URA3] pAV2565[yeIF5A-S149P LEU2] |
| GP7444 | GP7441 | pAV2580[heIF5A LEU2] |
| GP7446 | GP7443 | pAV2565[yeIF5A-S149P LEU2] |
| GP7447 | J696 | pAV2571[yeIF5A URA3] pAV2584[heIF5A-T48N LEU2] |
| GP7448 | J696 | pAV2571[yeIF5A URA3] pAV2585[heIF5A-G106R, LEU2] |
| GP7449 | J696 | pAV2571[yeIF5A URA3] pAV2586[heIF5A-R109Tfs*8 LEU2] |
| GP7450 | J696 | pAV2571[yeIF5A URA3] pAV2587[heIF5A-E122K LEU2] |
| GP7455 | GP7447 | pAV2584[heIF5A-T48N LEU2] |
| GP7456 | GP7450 | pAV2587[heIF5A-E122K LEU2] |
| GP7469 | GP7444 | pAV2580[heIF5A LEU2] pAV2592[heIF5A URA3] |
| GP7474 | GP7448 | pAV2585[heIF5A-G106R, LEU2] |
| GP7480 | GP7469 | pAV2592[heIF5A URA3] |
| GP7482 | GP7480 | pAV2592[heIF5A URA3] pAV2586[heIF5A-R109Tfs*8 LEU2] |
| GP7484 | GP7480 | pAV2592[heIF5A URA3] YCplac111[LEU2] |
| GP7485 | GP7480 | pAV2592[heIF5A URA3] pAV2590[heIF5A-R109Tfs*8 LEU2] |
| GP7490 | GP7444 | pAV2580[heIF5A LEU2] pAV2566[GALl promoter-LDB17-His6-HA-3C-ZZ URA3] |
| GP7491 | GP7455 | pAV2584[heIF5A-T48N LEU2] pAV2566[GAL1 promoter-LDB17-His6-HA-3C-ZZ URA3] |
| GP7492 | GP7474 | pAV2585[heIF5A-G106R, LEU2] pAV2566[GAL1 promoter-LDB17-His6-HA-3C-ZZ URA3] |
| GP7493 | GP7456 | pAV2587[heIF5A-E122K LEU2] pAV2566[GAL1 promoter-LDB17-His6-HA-3C-ZZ URA3] |
| GP7500 | GP7444 | pAV2580[heIF5A LEU2] pAV2570[GAL1 promoter-EAP1-His6-HA-3C-ZZ URA3] |
| GP7501 | GP7455 | pAV2584[heIF5A-T48N LEU2] pAV2570[GAL1 promoter-EAP1-His6-HA-3C-ZZ URA3] |
| GP7502 | GP7474 | pAV2585[heIF5A-G106R, LEU2] pAV2570[GAL1 promoter-EAP1-His6-HA-3C-ZZ URA3] |
| GP7503 | GP7456 | pAV2587[heIF5A-E122K LEU2] pAV2570[GAL1 promoter-EAP1-His6-HA-3C-ZZ URA3] |
| ${ }^{\text {a }}$ The genotype for all yeast strains is MATa trpl-63 ura3-52 leu2-3 leu2-112 GAL2+ gcn24 tif51b::NAT tif5la::KANMX4 from Saini, et al. ${ }^{2}$ but with the specific plasmids detailed above. All strains made for this study except J696 |  |  |

Individual 3's cDNA sequencing, Puromycin untreated - forward


Individual 3's cDNA sequencing, Puromycin untreated-reverse


Individual 3's cDNA sequencing, Puromycin treated-forward


Individual 3's cDNA sequencing, Puromycin treated - reverse


## Supplementary Figure 1. Individual 3 cDNA Sequencing.

Lymphoblastoid cells from Individual 3 were harvested either after 6-hrs-treatment with puromycin $(200 \mu \mathrm{~g} / \mathrm{mL})$ or not, washed in PBS and then kept at $-80^{\circ} \mathrm{C}$. After standard reverse transcription, cDNA from both conditions were Sanger sequenced bidirectionally. While cDNA sequences from puromycin untreated cells only show the WT allele, the cDNA sequences from puromycin treated cells show low peaks for other nucleotides compatible with the frameshift allele


Symbols


## Inserted variant

Yeast vector


## Supplementary Figure 2. Summary of the yeast strain construction.

A yeast codon and expression optimised hEIF5A cDNA was synthesised and cloned into yeast plasmid vectors, which were subsequently subject to site-directed mutagenesis. The J696 strain, with both TIF51A and TIF51B genes deleted, was transformed with the indicated vectors to create strains for this study.


## Supplementary Figure 3. Growth of human eIF5A alleles in yeast.

Growth of strains with indicated eIF5A alleles on synthetic dextrose (SD) plus Tryptophan (+W) (left) and SD+W+ Uracil (URA) + 5-
Fluoroorotic acid (5-FOA) incubated for $2,3,5$ and 10 days at $25^{\circ} \mathrm{C}, 30^{\circ} \mathrm{C}$ and $37^{\circ} \mathrm{C}$ (right). Small colonies with heIF5A p.T48N only (yellow circles) and p.G106R only (blue circle) were detected after 10 days. Eighteen replicates per temperature per condition were performed.


Supplementary Figure 4. Expression and hypusination of eIF5A-R109Tfs*8 in strains maintained with WT heIF5A.

Immunoblots showing eIF5A expression (left) and hypusination (Hyp; right) comparing heIF5A-R109Tfs*8 from single copy or high-copy (hc) plasmids co-expressed with heIF5AWT. WT only controls are also shown. Cells were grown at $30^{\circ} \mathrm{C}$ in SCD-URA-LEU liquid medium. Data presentation and statistical treatment as described for Fig. 2b. Where 2 alleles are expressed their levels were quantified separately as indicated by the labelled half-width bars. Full uncropped images of gel blots are shown in Supplementary Figure 9.


## Supplementary Figure 5. Possible results for polysome profiling of eIF5A variants

Under normal conditions (left panel), cells exhibit a Polysome-to-Monosome (P/M) ratio slightly above 1 , and a low $60 \mathrm{~S} / 80 \mathrm{~S}$ ratio. When there is a defect in translation initiation (middle panel), both the P/M and 60S/80S will be very low, whereas in translation elongation defects (right panel), the P/M ratio will be high and the $60 \mathrm{~S} / 80 \mathrm{~S}$ ratio will be low. While the former situation would reflect a loss of interaction of eIF5A with the ribosome, the latter would reflect an accumulation of eIF5A in the ribosome.


Supplementary Figure 6. Expression and hypusination of eIF5A alleles in Ldb17-HA

## PPT reporter strains.

eIF5A expression (left) and hypusination (Hyp; right) amongst yeast strains haploid for heIF5A with the Haemagglutinin (HA)-tagged Ldb17 reporter, grown at $30^{\circ} \mathrm{C}$ in SCGal medium. Data presentation and statistical treatment as described for Fig. 2b. Full uncropped images of gel blots are shown in Supplementary Figure 14.


Supplementary Figure 7. Expression and hypusination of eIF5A alleles in Eap1-HA

## PPT reporter strains.

eIF5A expression (left) and hypusination (Hyp; right) amongst yeast strains haploid for heIF5A with the Haemagglutinin (HA)-tagged Eap1 reporter, grown at $30^{\circ} \mathrm{C}$ in SCGal medium. Data presentation and statistical treatment as described for Fig. 2b. Full uncropped images of gel blots are shown in Supplementary Figure 15.

## $2^{\text {nd }}$ DAY $-30^{\circ} \mathrm{C}$ <br> SD+W+Uracil



Supplementary Figure 8. Extended Figure 3a. Growth of Yeast strains with Spermidine
Growth of yeast strains haploid for human eIF5A (heIF5A) or its variants in minimum media supplemented with 0 mM (Untreated), $1 \mathrm{mM}, 2 \mathrm{mM}$ and 5 mM of spermidine at $30^{\circ} \mathrm{C}$ until day 2. Eighteen replicates per condition were performed.


## Supplementary Figure 9. Full scans of western blots shown in Fig $\mathbf{2 b}$ and Supplementary Fig 4.

Scans of molecular weight marker, eIF5A, Hypusine and loading control (Pab1). The black boxes and black dashed-line boxes depict the areas shown in Fig. 2b and in Supplementary Fig 4, respectively.

kDa

uL29

hEIF5A E112K
hEIF5A G106R

elF5A



kDa
 $20-\square$


Supplementary Figure 10. Full scans of western blots shown in Fig 2c.
Scans of proteins tested (rows) in polysome profiles according to the strain tested (columns). The black boxes depict the areas shown in Fig. 2c.


## Supplementary Figure 11. Full scans of western blots shown in Fig 2d.

Scans of molecular weight marker, HA-tagged reporters (Ldb17 and Eap1) and loading controls (eIF2 $\alpha$ and Pab1). The black boxes depict the areas shown in Fig. 2d.


Scans of proteins tested (rows) in polysome profiles under 1 mM spermidine treatment according to the strain tested (columns). The black boxes depict the areas shown in Fig. 3b.


Supplementary Figure 13. Full scans of western blots shown in Fig 3c.
Scans of molecular weight marker, HA-tagged reporter (Ldb17), eIF5A, hypusine and loading control (eIF2 $\alpha$ ) from strains untreated (first four lanes) and treated with 1 mM spermidine (last four lanes). The black boxes depict the areas shown in Fig. 2d


## Supplementary Figure 14. Full scans of western blots shown in Supplementary Fig 6.

Scans of molecular weight marker, eIF5A, hypusine and loading control (eIF2 $\alpha$ ) from strains with HA-tagged Ldb17 reporter. The black boxes depict the areas shown in Supplementary Fig. 6


Supplementary Figure 15. Full scans of western blots shown in Supplementary Fig 7.
Scans of molecular weight marker, eIF5A, hypusine and loading control (Pab1) from strains with HA-tagged Eap1 reporter. The black boxes depict the areas shown in Supplementary Fig. 7

## Supplementary References

1. Rizzardi, L.F., Dorn, E.S., Strahl, B.D. \& Cook, J.G. DNA Replication Origin Function Is Promoted by H3K4 Di-methylation in Saccharomyces cerevisiae. Genetics 192, 371-384 (2012).
2. Saini, P., Eyler, D.E., Green, R. \& Dever, T.E. Hypusine-containing protein eIF5A promotes translation elongation. Nature 459, 118-21 (2009).
3. Gutierrez, E. et al. eIF5A promotes translation of polyproline motifs. Mol Cell 51, 35-45 (2013).
